Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, ...
Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...
The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...
The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...
USA-based mRNA vaccines company Moderna’s shares were flat in pre-market activity, as the company announced awaited new ...
Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British ...
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
Merck CEO Rob Davis expressed high confidence during the company’s J.P. Morgan presentation on Monday, revealing that the ...
Guardant Health recently announced a multi-year collaboration with Merck to use its Guardant Infinity Smart liquid and tissue biopsy platform to support Merck’s global oncology clinical trials, ...
Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback